KRAKOW, Poland, Sept. 28, 2022 /PRNewswire/ — Ryvu Therapeutics (WSE: RVU), a scientific-phase drug discovery and development firm concentrating on novel modest molecule therapies that tackle rising targets in oncology, right now documented economic effects for the first fifty percent of 2022 and delivered a company update. In August, Ryvu secured €22 […]
Corporate
Kintara Therapeutics Announces Fiscal 2022 Financial Results and Provides Corporate Update
SAN DIEGO, Sept. 27, 2022 /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal year ended June 30, 2022 and provided a corporate update. CORPORATE HIGHLIGHTS AND RECENT […]
Kiwetinohk updates corporate presentation and is scheduled to present at the Peters & Co. Limited’s 2022 Energy Conference
CALGARY, AB, Sept. 14, 2022 /CNW/ – Kiwetinohk Energy Corp. (TSX: KEC) today announced it has updated its corporate presentation now available on its website at www.kiwetinohk.com. Jakub Brogowski, Chief Financial Officer, will be presenting at the Peters & Co. Limited’s 2022 Energy Conference at 10:00 AM Eastern Time on […]
Relief Reports Half-Year 2022 Results and Provides Corporate Update
GENEVA, SWITZERLAND / ACCESSWIRE / September 15, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (“Relief”), a Swiss, commercial-stage biopharmaceutical company seeking to provide patients therapeutic benefit from selected specialty, rare and ultra-rare diseases with high unmet need, today reported its results for the half-year ended June 30, 2022 and provided […]
Progressive Corporate Information Update Drilling Tender, Administrators, Funding, Marketing and advertising
One of the Historic Earlier Creating Copper Mines Phoenix Copper Gold Mine Greenwood BC VANCOUVER, BC / ACCESSWIRE / September 6, 2022 / Golden Dawn Minerals Inc., (TSXV:GOM | FRANKFURT:3G8C | OTC PINK:GDMRD), (“Golden Dawn” or the “Firm“), is at the moment examining a corporate restructuring which may well involve […]
Junshi Biosciences Announces 2022 Interim Financial Results and Provides Corporate Updates
Junshi Biosciences — Clinical trials of core drug candidates are progressing steadily with the debut of the company’s FIH asset — Toripalimab’s sales performance is consistently improving; the US BLA is under review SHANGHAI, China, Aug. 31, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; […]
Victory Square Technologies Reports 2022 Q2 Financial Results & Corporate Update
Victory Square Technologies Inc. 2022 Q2 unaudited Net Asset Value (“NAV”) of $89,704,469 as at June 30, 2022 Notable Portfolio Highlights: IV Hydreight, Creator.co, GameOn, XR Immersive, Next Decentrum, Stardust Solar, CoPilot, Fansunite, Turnium, Covalent CQT and CloudAdvisors Company & Executive Team featured in Forbes, Yahoo Finance, Entrepreneur, CoinTelegraph and […]
Antengene Announces Interim 2022 Financial Results and Provides Corporate Update
– Revenue of RMB 53.96 million mainly driven by the commercial launch of XPOVIO® (selinexor) in Mainland China on May 13, 2022 – Adjusted loss reduced to RMB 126 million for the first six months of 2022 from RMB 210 million in the same period last year – Cash and bank balances […]
Kinarus Therapeutics Reports H1 2022 Financial Results and Provides Corporate Update
Kinarus Therapeutic Holding AG Interim data from Phase 2 KINETIC clinical trial of KIN001 to treat hospitalized COVID-19 patients expected in Q3 2022 First patient dosed with in Phase 2 KINFAST clinical trial with ambulatory COVID-19 mild-patients Signed a CHF 20 million financing with Yorkville Advisors Fully financed until Q1 […]
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2022 Financial Results
Quoin Pharmaceuticals, Inc. Initiates clinical trial evaluating lead product candidate, QRX003 for Netherton SyndromeExpands number of commercial partnerships to eight, covering 60 countriesSigns Research Agreement to develop a product for the treatment of scleroderma Closes $16.8 million public offering, with net proceeds of approximately $15.0 million ASHBURN, Va., Aug. 18, […]